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Correspondence
ATRA administration in the critically ill patient
A\\-trans retinoic acid (ATRA) is now widely used as induction 
therapy for acute promyelocytic leukaemia. Recently, we 
needed to give ATRA via a naso-gastric (NG) tube, and could 
find no information about such administration in the literature. 
We report successful administration when the liquid was 
mixed with soya oil.
A 12-year-old boy presented with melaena, anaemia and 
gum bleeding. He was confused, oxygen-dependent and CXR 
showed an infiltrate. The blood count showed a WBC of 
49 X 109/l with 64% blasts. Marrow morphology was typical 
of AML M3 and marrow cytogenetics demonstrated t(15;17). 
The patient's high WBC and respiratory status made initial 
therapy with ATRA inappropriate until the leukaemia burden 
was reduced. He therefore commenced induction chemo­
therapy with idarubicin, cytosine and thioguanine. His respir­
atory status deteriorated, and he required ventilation 24 h 
later. Therapy with ATRA (Roche Pty Ltd, Sydney, Australia) 
was initiated 48 h after chemotherapy, when his WBC was
6 X 107!, at a dose of 40 mg (25 mg/m2) daily. The patient 
was muscle-relaxed with a NG tube in place. Attempts to 
aspirate the ATRA from the capsules was hampered by it stick­
ing to both plastic or glass syringes. Flushing the viscous fluid 
with saline or water was also unsuccessful. The parent drug 
company had no information on use of ATRA via an NG tube, 
and no parenteral preparation is available. However, the 
reason that the solution is so viscous is that the ATRA is 
emulsified in soya oil.
Our solution to this problem was as follows. The capsules 
of ATRA were cut open and the contents aspirated via a 19- 
gauge needle into a syringe which had been primed with 1 ml 
of soya bean oil. After aspiration, on visual inspection, the
capsule retained about half of the original volume of the drug. 
Small amounts of soya bean oil were mixed with the capsule 
contents. The resulting reduction in viscosity of the capsule 
contents allowed more of the ATRA to be drawn up into a 
syringe. The remaining liquid was flushed out with fresh soya­
bean oil. The resulting mixture of ATRA and soyabean oil was 
stirred to ensure uniformity, placed in a glass syringe and 
administered via the NG tube within 24 h of preparation.
After 14 days of ATRA administration, plasma levels were 
measured using a modified version of the method of Smith 
and colleagues.1 Levels of ATRA rose from 1,4 to 2.2 jxM after 
the dose. Such high levels and only a minimal increase in 
response to the additional dose suggest saturation pharmoco- 
kinetics similar to the day 28 disposition of ATRA previously 
reported,1
As patients diagnosed with M3 AML frequently have prob­
lems with bleeding and infection, we were surprised to find 
no information on naso-gastric administration of ATRA. As it 
took several days to acquire the information that allowed us 
to find a solution for the final method of ATRA administration, 
we hope this information may be of use to other clinicians 
who find themselves in the same situation.
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Comment on published paper (Proctor et a!, this issue pp 1246-1251)
Selection biases play a major role in the evaluation of bone 
marrow transplantation. It is generally assumed that more fav­
orable subgroups of patients are subjected to allogeneic BMT. 
Patients in poor clinical condition or patients who relapse 
early are usually excluded from this procedure. Only prospec­
tive randomized studies or population-based studies are suit­
able approaches to evaluate the impact of allogeneic BMT on 
survival. Even prospective randomized studies suffer from 
selection bias throughout the treatment protocol. For instance 
in the recently published EORTC/EBMT AML 8a study1 HLA 
typing was only performed in 80% of the patients. Out of the 
230 patients in complete remission with a histocompatible
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sibling donor 168 patients were proposed for allografting and 
only 144 patients received the allograft. An intention-to-treat 
analysis resolved this selection bias partly, but the full impact 
of allogeneic BMT could not be assessed because not all pati­
ents were HLA-typed and not all patients were assigned to 
allogeneic BMT.
For that reason the population-based study of Proctor et af2 
(this issue) is very interesting and deserves attention. A strik­
ingly high proportion of patients had a donor (78%) for which 
no good explanation can be given except for chance. In the 
age group 15 to 40-years-old, 28 patients had a donor. Three 
patients were excluded from the intention-to-treat analysis, 
because of refusal (two patients) or preference for autologous 
BMT (one patient). These patients should have been included 
in the intention-to-treat analysis. Nevertheless, the event-free
%
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survival of the remaining 25 patients with a histocompatible 
sibling donor was significantly better than the EF5 of patients 
of the same age who received chemotherapy alone.
This study shows that population-based studies are very 
important and useful. We should congratulate Dr Proctor and 
his co-workers for their efforts and stimulate others to pursue 
analyses based on the same principles.
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Hematopoietic growth factors in drug-induced agranulocytosis
Sprikkelman et aP published in your columns an extensive 
review on the therapeutic benefit from growth factors in pati­
ents with drug-induced agranulocytosis. We feel that the evi­
dence presented does not substantiate the conclusion that 'G- 
CSF and GM-CSF enhance the recovery of the myeloid lin­
eage, resulting in a faster normalization of the peripheral 
blood granulocyte count and a reduced incidence of fatal 
complications'. Comparing the duration of agranulocytosis in 
patients treated or not treated with growth factors on the basis 
of the available literature is misleading: most patients given 
growth factors were reported as 'case reports7 (60 patients 
were collected from 31 references), while the data on patients 
not being given growth factors result from population-based 
studies, encompassing all patients with drug-induced agranu­
locytosis observed in a given period of time. In the former 
case, a bias towards reporting patients with a favorable out­
come can be reasonably suspected; most investigators would 
refrain from reporting patients given growth factors and 
recovering in a not unexpected period of time. Moreover, the 
editorial policy of some journals but not Leukemia favors the 
publication of optimistic case reports: our first paper reporting 
a prompt recovery in a patient treated with GM-CSF was 
immediately accepted for publication;2 when, after treating 
three additional patients with less success, we submitted a 
'word of caution' to the same editor, it was rejected and final ly 
published elsewhere . . .  .3
More basically, if, as underlined by Sprikkelman et al, most 
cases of agranulocytosis are antibody-mediated, growth fac­
tors are unlikely to be of great help as long as the offending 
antibody is present. At best, growth factors could contribute 
to neutrophil recovery relatively late during the course of 
agranulocytosis, when the offending antibody or drug-anti-
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body complex has been cleared, To some extent, this view is 
supported by Tamai et al4 who conclude that G-CSF hastens 
recovery in patients already on their way to recovery.
In conclusion/ we feel that the efficacy of growth factors in 
drug-induced agranulocytosis has not been convincingly dem­
onstrated. Treating agranulocytosis with growth factors on a 
routine basis is premature, especially as severe adverse reac­
tions may result from their use.-1’
A DELANNOY Hôpital de Joli mont,
and C RAVOET Hematology Department,
7100 Ha in e -Sa in t- Pa u I,
Belgium
References
1 Sprikkelman A, de Wolf JThM, Vellenga E. The application of hem­
atopoietic growth factors in drug-induced agranulocytosis: a 
review of 70 cases. Leukemia 1994; 8: 2031-2036.
2 Delannoy A, Gehenot M. Colony-stimulating factor and drug- 
induced agranulocytosis. Ann Intern M ed  1989; 110: 942 (letter).
3 Delannoy A. GM-CSF therapy for drug-induced agranulocytosis, j  
Intern M e d  1992; 231: 269-271.
4 Tamai H eta l. Treatment of methimazole-induced agranulocytosis 
using recombinant human granulocyte colohy-stimulating factor 
(rhG-CSF). J Clin Endocrino l Metab  1993; 77: 1356-1360.
5 Boogaerts MA, Demuynck H, Zachee P, Verhoef G. ARDS during 
G-CSF therapy for drug-induced agranulocytosis. B lood  1993; 82: 
1964a (abstr.).
Note from the editor
Policy underlying acceptance of papers is complex. As far as 
Leukemia is concerned, we relish debates and provided stat- 
ments are circumstantiated by fa c ts  -  our major criterion -  
contradictory data are always published.
